Stockreport

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year [Seeking Alpha]

Viridian Therapeutics, Inc.  (VRDN) 
PDF THRIVE-1 and THRIVE-2 phase 3 results of VRDN-001 in TED patients are the most important catalysts for the company this year. Matching Tepezza's efficacy and safety w [Read more]